Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 201
Key Takeaways
Risk factor
High price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Data is available to registered users only
Target Price
The average target price of 6535.TWO is 360 and suggests 79% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Data is available to registered users only
Buy
Sell